Facultad de Medicina y Nutrición, Universidad Juárez del Estado de Durango, Av. Universidad y Fanny Anitúa S/N, Durango, Durango C.P. 34000, Mexico.
Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Ciudad de México C.P. 04510, Mexico.
Molecules. 2017 Dec 20;22(12):2262. doi: 10.3390/molecules22122262.
The Atlas of Diabetes reports 415 million diabetics in the world, a number that has surpassed in half the expected time the twenty year projection. Type 2 diabetes is the most frequent form of the disease; it is characterized by a defect in the secretion of insulin and a resistance in its target organs. In the search for new antidiabetic drugs, one of the principal strategies consists in promoting the action of insulin. In this sense, attention has been centered in the protein tyrosine phosphatase 1B (PTP1B), a protein whose overexpression or increase of its activity has been related in many studies with insulin resistance. In the present work, a chemical library of 250 compounds was evaluated to determine their inhibition capability on the protein PTP1B. Ten molecules inhibited over the 50% of the activity of the PTP1B, the three most potent molecules were selected for its characterization, reporting Ki values of 5.2, 4.2 and 41.3 µM, for compounds , , and , respectively. Docking and molecular dynamics studies revealed that the three inhibitors made interactions with residues at the secondary binding site to phosphate, exclusive for PTP1B. The data reported here support these compounds as hits for the design more potent and selective inhibitors against PTP1B in the search of new antidiabetic treatment.
《糖尿病图集》报告称,全球有 4.15 亿糖尿病患者,这一数字在预计的 20 年内超过了预期的一半。2 型糖尿病是最常见的糖尿病形式,其特征是胰岛素分泌缺陷和靶器官对胰岛素的抵抗。在寻找新的抗糖尿病药物时,主要策略之一是促进胰岛素的作用。在这方面,人们关注的焦点是蛋白酪氨酸磷酸酶 1B(PTP1B),许多研究表明,这种蛋白质的过度表达或活性增加与胰岛素抵抗有关。在本工作中,评估了一个包含 250 种化合物的化学文库,以确定它们对蛋白质 PTP1B 的抑制能力。有 10 种化合物对 PTP1B 的活性抑制超过 50%,选择了三种最有效的化合物进行表征,其 Ki 值分别为 5.2、4.2 和 41.3µM,对应的化合物分别为 、 、 。对接和分子动力学研究表明,这三种抑制剂与磷酸的二级结合位点的残基相互作用,这是 PTP1B 所特有的。这里报道的数据支持这些化合物作为新的抗糖尿病治疗方法中针对 PTP1B 的更有效和选择性抑制剂的潜在药物。